These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15206501)

  • 1. FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer in chronic obstructive pulmonary disease.
    Muir JF; Benhamou D; Cuvelier A; Le Gros V; Overend T; Till D; Della Cioppa G; Kottakis J
    Int J Clin Pract; 2004 May; 58(5):457-64. PubMed ID: 15206501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
    Molimard M; Bourcereau J; Le Gros V; Bourdeix I
    Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
    Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K;
    Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD.
    Cazzola M; Santus P; Matera MG; Carlucci P; Belloli E; Di Marco F; Centanni S
    Respir Med; 2003 May; 97(5):458-62. PubMed ID: 12735660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
    Quinn D; Seale JP; Reisner C; Fischer T; Golden M; Fernandez C; Darken P; St Rose E; Thomas M; Tardie G; Orevillo C
    Respir Med; 2014 Sep; 108(9):1327-35. PubMed ID: 25060541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
    Hogan TJ; Geddes R; Gonzalez ER
    Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
    Aalbers R; Ayres J; Backer V; Decramer M; Lier PA; Magyar P; Malolepszy J; Ruffin R; Sybrecht GW
    Eur Respir J; 2002 May; 19(5):936-43. PubMed ID: 12030736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immediate bronchodilator response to formoterol in poorly reversible chronic obstructive pulmonary disease].
    Rubin AS; Souza FJ; Hetzel JL; Moreira Jda S
    J Bras Pneumol; 2008 Jun; 34(6):373-9. PubMed ID: 18622504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD.
    Liesker JJ; Van De Velde V; Meysman M; Vincken W; Wollmer P; Hansson L; Kerstjens HA; Qvint U; Pauwels RA
    Respir Med; 2002 Aug; 96(8):559-66. PubMed ID: 12195835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.
    Prenner BM
    Expert Opin Pharmacother; 2007 Dec; 8(17):3069-84. PubMed ID: 18001266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
    Cazzola M; Noschese P; Salzillo A; De Giglio C; D'Amato G; Matera MG
    Respir Med; 2005 May; 99(5):524-8. PubMed ID: 15823447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease.
    Centanni S; Di Marco F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2525-34. PubMed ID: 16259583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
    Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
    Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.